{"id":935449,"date":"2026-02-10T07:00:43","date_gmt":"2026-02-10T12:00:43","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/pharvaris-to-present-clinical-data-at-the-aaaai-2026-annual-meeting\/"},"modified":"2026-02-10T07:00:43","modified_gmt":"2026-02-10T12:00:43","slug":"pharvaris-to-present-clinical-data-at-the-aaaai-2026-annual-meeting","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/pharvaris-to-present-clinical-data-at-the-aaaai-2026-annual-meeting\/","title":{"rendered":"Pharvaris to Present Clinical Data at the AAAAI 2026 Annual Meeting"},"content":{"rendered":"

\nPivotal Phase 3 data from RAPIDe-3 of deucrictibant for the on-demand treatment of HAE attacks to be presented for the first time
\n<\/h2>\n
\n

ZUG, Switzerland, Feb. 10, 2026 (GLOBE NEWSWIRE) — Pharvaris<\/a> (Nasdaq: PHVS), a late-stage biopharmaceutical company developing novel, oral bradykinin B2 receptor antagonists to help address unmet needs of those living with bradykinin-mediated diseases such as hereditary angioedema (HAE) and acquired angioedema due to C1 inhibitor deficiency (AAE-C1INH), announced the acceptance of six abstracts for poster presentation, three of which will be presented during the Featured Poster session, at the American Academy of Allergy, Asthma & Immunology (AAAAI) 2026 Annual Meeting<\/a>, to be held from February 27-March 2, 2026, in Philadelphia, PA.<\/p>\n

\u201cFollowing the announcement of topline RAPIDe-3 data in December of last year, the AAAAI Annual Meeting provides Pharvaris with the first opportunity to share the positive study results with the broader medical community at a large scientific congress,\u201d said Peng Lu, M.D., Ph.D., Chief Medical Officer of Pharvaris. \u201cWe will also be presenting final data from the open-label portion of CHAPTER-1, the Phase 2 study of deucrictibant for prophylaxis of HAE attacks, and pharmacokinetic data of deucrictibant extended-release tablet, which is being used in the pivotal Phase 3 study of deucrictibant for long-term prophylaxis of HAE attacks, CHAPTER-3. Final efficacy and safety results from approximately three years of deucrictibant treatment from CHAPTER-1 and the data providing further evidence of an optimized extended-release formulation provide strong foundations in advance of the results of CHAPTER-3, topline data from which is anticipated in the third quarter of this year. Additionally, we will be presenting on-demand endpoint validation findings, as well as results from our novel kinin biomarker assay.\u201d<\/p>\n

Details of the presentations are as follows:<\/p>\n